Paclitaxel in patients with advanced angiosarcomas of soft tissue: A retrospective study of the EORTC soft tissue and bone sarcoma group

European Journal of Cancer

Volumn 44, Issue 16, 2008, Pages 2433-2436

  Schlemmer, M ^a   Reichardt, P ^b   Verweij, J ^c   Hartmann, J T ^d   Judson, I ^e   Thyss, A ^f   Hogendoorn, P C W ^g   Marreaud, S ^h   Glabbeke, M Van ^h   Blay, J Y ⁱ  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b HELIOS Klinikum Bad Saarow   (Germany)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e ROYAL MARSDEN HOSPITAL   (United Kingdom)

^f CENTRE ANTOINE LACASSAGNE   (France)

^g LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^h EORTC DATA CENTER   (Belgium)

ⁱ UNIVERSITÉ LYON 1   (France)

Author keywords

Angiosarcoma; Paclitaxel

Indexed keywords

DOXORUBICIN; IFOSFAMIDE; PACLITAXEL;

ADULT; AGED; ANGIOSARCOMA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COMPUTER PROGRAM; FACE; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCALP; SOFT TISSUE ANGIOSARCOMA; STATISTICAL ANALYSIS; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; FACIAL NEOPLASMS; FEMALE; HEMANGIOSARCOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; RETROSPECTIVE STUDIES; SCALP; SKIN NEOPLASMS; SOFT TISSUE NEOPLASMS; YOUNG ADULT;

EID: 54449099288     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.07.037     Document Type: Article

References (24)

1. Mark R.J., Poen J.C., Tran L.M., et al. Angiosarcoma. A report of 67 patients and a review of the literature. Cancer 77 (1996) 2400-2406
2. Vorburger S.A., Xing Y., Hunt K.K., et al. Angiosarcoma of the breast. Cancer 104 (2005) 2682-2688
3. DeBree E., van Coevorden F., Peterse J.L., et al. Bilateral angiosarcoma of the breast after conservative treatment of bilateral invasive carcinoma: genetic predisposition?. Eur J Surg Oncol 28 (2002) 392-395
4. Holden C.A., Spittle M.F., and Jones E.W. Angiosarcoma of the face and scalp, prognosis and treatment. Cancer 59 (1987) 1046-1057
5. Aust K.D., Olsen M.R., Lewis J.E., et al. Angiosarcomas of the head and neck: clinical and pathological characteristics. Ann Otol Rhinol Laryngol 106 (1997) 943-951
6. Meis-Kindblom J.M., and Kindblom L.G. Angiosarcoma of soft tissue: a study of 80 cases. Am J Surg Pathol 22 (1998) 683-697
7. Espat N.J., Lewis J.J., Woodruff J.M., et al. Confirmed angiosarcoma: prognostic factors and outcome in 50 prospectively followed patients. Sarcoma 4 (2000) 173-177
8. McIntosh B.C., and Narayan D. Head and neck angiosarcomas. J Craniofac Surg 16 (2005) 699-703
9. Pawlik T.M., Paulino A.F., Mcginn C.J., et al. Cutaneous angiosarcoma of the scalp a multidisciplinary approach. Cancer 98 (2003) 1716-1726
10. Balcerzak S., Benedetti J., Weiss G., et al. A phase II trial of paclitaxel in patients with advanced soft tissue sarcomas: a SWOG study. Cancer 76 (1995) 2248-2252
11. Patel S., Linke K., Burgess A., et al. Phase II study of paclitaxel in patients with soft tissue sarcomas. Sarcoma 1 (1997) 95-97
12. Rowinsky E.K., and Donehower R.C. Paclitaxel. New Engl J Med 332 (1995) 1004-1014
13. Belotti D., Vergani V., Drudis T., et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 2 (1996) 1843-1849
14. Klauber N., Parangi S., Hamel E., et al. Inhibition of angiogenesis in vivo by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 57 (1997) 81-86
15. Fata F., O'Reilly E., Ilson D., et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 86 (1999) 2034-2037
16. Casper E.S., Waltzman R.J., Schwartz G.K., et al. Phase II trial of paclitaxel in patients with soft-tissue sarcoma. Cancer Invest 16 (1998) 442-446
17. Fury M.G., Antonescu C.R., Van Zee K.J., Brennan M.F., and Maki R.G. A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J 11 (2005) 241-247
18. Hensley M.L., Maki R., Venkatraman E., et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 20 (2002) 2824-2831
19. Grosso F., Jones R.L., Demetri G.D., et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 8 (2007) 595-602
20. Verweij J., Casali P.G., Zalcberg J., et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364 (2004) 1127-1134
21. Demetri G.D., van Oosterom A.T., Garrett C.R., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368 (2006) 1329-1338
22. Verweij J., Lee S.M., Ruka W., et al. Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the European organization for research and treatment of cancer soft tissue and bone sarcoma group. J Clin Oncol 18 (2000) 2081-2086
23. Penel N., Lansiaux A., and Adenis A. Angiosarcomas and taxanes. Curr Treat Options Oncol (2007) 428-434
24. Fraiman G., Ganti A.K., Potti A., et al. Angiosarcoma of the small-intestine: a possible role for thalidomide?. Med Oncol 20 (2003) 397-492